Arcutis Biotherapeutics Inc

詳細情報 Arcutis Biotherapeutics Inc 企業名

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

企業情報

企業コードARQT

会社名Arcutis Biotherapeutics Inc

上場日Jan 31, 2020

最高経営責任者「CEO」Mr. Todd Franklin Watanabe

従業員数342

証券種類Ordinary Share

決算期末Jan 31

本社所在地3027 Townsgate Road

都市WESTLAKE VILLAGE

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号91361

電話番号18054185006

ウェブサイトhttps://arcutis.com/

企業コードARQT

上場日Jan 31, 2020

最高経営責任者「CEO」Mr. Todd Franklin Watanabe

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Bhaskar Chaudhuri, Ph.D.

Independent Director

917.81K

+0.84%

Mr. Todd Franklin Watanabe

President, Chief Executive Officer, Director

721.32K

-0.28%

Dr. Howard G. Welgus, M.D.

Independent Director

100.21K

-8.42%

Mr. Masaru (Mas) Matsuda, Esq., J.D.

Senior Vice President, General Counsel

78.26K

-8.03%

Ms. Latha Vairavan

Chief Financial Officer, Senior Vice President

65.10K

--

Ms. Sue-Jean Lin

Independent Director

26.73K

+39.78%

Mr. Patrick J. Heron

Independent Chairman of the Board

26.43K

+40.42%

Ms. Neha Krishnamohan

Independent Director

23.36K

+48.32%

Ms. Terrie J. Curran

Independent Director

--

Ms. Halley E. Gilbert, J.D.

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Bhaskar Chaudhuri, Ph.D.

Independent Director

917.81K

+0.84%

Mr. Todd Franklin Watanabe

President, Chief Executive Officer, Director

721.32K

-0.28%

Dr. Howard G. Welgus, M.D.

Independent Director

100.21K

-8.42%

Mr. Masaru (Mas) Matsuda, Esq., J.D.

Senior Vice President, General Counsel

78.26K

-8.03%

Ms. Latha Vairavan

Chief Financial Officer, Senior Vice President

65.10K

--

Ms. Sue-Jean Lin

Independent Director

26.73K

+39.78%

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, May 17

株主統計

種類

株主統計

比率

Suvretta Capital Management, LLC

9.58%

Jennison Associates LLC

9.32%

Rubric Capital Management LP

9.20%

Frazier Life Sciences Management, L.P.

7.37%

BlackRock Institutional Trust Company, N.A.

6.63%

Other

57.89%

株主統計

比率

Suvretta Capital Management, LLC

9.58%

Jennison Associates LLC

9.32%

Rubric Capital Management LP

9.20%

Frazier Life Sciences Management, L.P.

7.37%

BlackRock Institutional Trust Company, N.A.

6.63%

Other

57.89%

種類

株主統計

比率

Investment Advisor

32.24%

Investment Advisor/Hedge Fund

31.96%

Hedge Fund

29.96%

Private Equity

7.39%

Research Firm

4.30%

Individual Investor

2.19%

Venture Capital

1.84%

Sovereign Wealth Fund

0.45%

Bank and Trust

0.42%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

477

132.39M

111.07%

-21.95M

2025Q1

487

132.87M

111.51%

-24.00M

2024Q4

453

136.04M

114.96%

-23.73M

2024Q3

433

136.12M

116.66%

-19.10M

2024Q2

416

134.94M

116.78%

-20.37M

2024Q1

392

131.83M

115.81%

+2.26M

2023Q4

366

104.30M

108.66%

+5.22M

2023Q3

364

79.57M

131.78%

-15.32M

2023Q2

359

84.02M

139.44%

-6.66M

2023Q1

352

83.59M

140.11%

+3.40M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Suvretta Capital Management, LLC

11.42M

9.58%

+23.84K

+0.21%

Mar 31, 2025

Jennison Associates LLC

11.36M

9.53%

-978.92K

-7.93%

Mar 31, 2025

Rubric Capital Management LP

10.97M

9.2%

--

Mar 31, 2025

Frazier Life Sciences Management, L.P.

8.79M

7.37%

--

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

7.91M

6.63%

-197.41K

-2.44%

Mar 31, 2025

The Vanguard Group, Inc.

6.79M

5.7%

+373.66K

+5.82%

Mar 31, 2025

Polar Capital LLP

6.71M

5.63%

-670.91K

-9.09%

Mar 31, 2025

State Street Global Advisors (US)

4.47M

3.75%

-476.52K

-9.63%

Mar 31, 2025

Gilder Gagnon Howe & Co. LLC

4.10M

3.44%

+193.06K

+4.95%

Mar 31, 2025

Morgan Stanley & Co. LLC

3.08M

2.58%

-403.45K

-11.59%

Mar 31, 2025

詳細を見る

14.348USD

Arcutis Biotherapeutics Inc

14.348

概要

企業名

金融